A new drug for the treatment of idiopathic pulmonary fibrosis, Pirfenidone, has been registered
Mirpharm announces the successful registration of a new drug for the treatment of idiopathic pulmonary fibrosis (IPF) in the form of capsules.
Moscow, July 2022
Pirfenidone is an immunosuppressive agent with antifibrosing and anti-inflammatory characteristics in multiple in vitro systems and in animal models of pulmonary fibrosis (bleomycin-transplant-induced fibrosis).
Idiopathic pulmonary fibrosis (IPF) is a chronic fibrosing and inflammatory lung disease caused by the synthesis and release of proinflammatory cytokines, including tumor necrosis factor alpha (TNFα) and interleukin-1-beta (IL-1β). Pirfenidone is able to reduce the accumulation of inflammatory cells in response to various stimuli.
Pirfenidone reduces fibroblast proliferation, production of fibrosis-associated proteins and cytokines, and increases interstitial matrix biosynthesis and accumulation in response to cytokine growth factors such as transforming growth factor beta (TGFβ and platelet growth factor (PGF).
Available dosages: 267 mg in packages of 90 and 270 capsules.
Note:
The press release contains information about prescription medications. Use of this information for preparation of publications must be made in accordance with the legislation of the Russian Federation on advertising, (including but not limited to Art. 24 of the Federal Law of 13.03.2006 No. 38-FL "On Advertising"), according to which, in particular, advertising of prescription drugs is allowed only in places of medical or pharmaceutical exhibitions, workshops, conferences and other similar events as well as in specialized print media intended for medical and pharmaceutical workers. Failure to comply with the above requirements (namely, mentioning the name of the drug, placing an image of the package or its elements in the media other than specialized print publications intended for medical and pharmaceutical workers) shall entail administrative liability.